Methotrexate News and Research

RSS
Methotrexate is an antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.

Methotrexate is approved by the Food and Drug Administration (FDA) to be used by itself to treat the following types of gestational trophoblastic tumors, Chorioadenoma destruens, Choriocarcinoma, Hydatidiform mole. Methotrexate is also approved to be used alone or with other drugs to treat acute lymphoblastic leukemia (ALL) that has spread to the central nervous system (CNS) or to keep it from spreading there, and to treat the following, breast cancer, certain types of head and neck cancer, lung cancer, advanced non-Hodgkin lymphoma (NHL), advanced mycosis fungoides (a type of cutaneous T-cell lymphoma), osteosarcoma that has not spread to other parts of the body, following surgery to remove the primary tumor. Methotrexate is also approved to treat the following non-cancer conditions, rheumatoid arthritis, severe psoriasis.
Juvenile immune arthritis – new treatments wanted

Juvenile immune arthritis – new treatments wanted

Methotrexate reduces joint damage in hand osteoarthritis

Methotrexate reduces joint damage in hand osteoarthritis

Study compares ultrasound versus conventional strategies in early rheumatoid arthritis

Study compares ultrasound versus conventional strategies in early rheumatoid arthritis

Cancer patients with RA treated with immune checkpoint inhibitors likely to experience a flare

Cancer patients with RA treated with immune checkpoint inhibitors likely to experience a flare

Methotrexate appears to facilitate bone remodeling in patients with osteoarthritis

Methotrexate appears to facilitate bone remodeling in patients with osteoarthritis

Optimal therapy for Down syndrome arthropathy remains unclear, reveals study

Optimal therapy for Down syndrome arthropathy remains unclear, reveals study

Study provides first data on infectious risk in children exposed to non-TNFi biologics and tofacitinib

Study provides first data on infectious risk in children exposed to non-TNFi biologics and tofacitinib

Children with Down syndrome at greater risk of an associated form of arthritis

Children with Down syndrome at greater risk of an associated form of arthritis

Study reveals safety, efficacy of live zoster vaccine for people taking TNF inhibitors

Study reveals safety, efficacy of live zoster vaccine for people taking TNF inhibitors

Two uveitis drugs perform similarly in a head-to-head clinical trial

Two uveitis drugs perform similarly in a head-to-head clinical trial

Combination therapy for rheumatoid arthritis may lead to higher remission rates

Combination therapy for rheumatoid arthritis may lead to higher remission rates

Still-to-be-approved drug proves to be new option for treating active rheumatoid arthritis

Still-to-be-approved drug proves to be new option for treating active rheumatoid arthritis

Surgery can be beneficial for one type of primary central nervous system lymphoma

Surgery can be beneficial for one type of primary central nervous system lymphoma

ACR and Arthritis Foundation release two guidelines on juvenile idiopathic arthritis

ACR and Arthritis Foundation release two guidelines on juvenile idiopathic arthritis

Promising new way to thwart tricky Mtb pathogen

Promising new way to thwart tricky Mtb pathogen

Machine learning tool could prevent unnecessary treatments for kids with arthritis

Machine learning tool could prevent unnecessary treatments for kids with arthritis

New discovery can explain resistance of cancer types to fatty acid metabolism inhibition

New discovery can explain resistance of cancer types to fatty acid metabolism inhibition

Monoclonal antibody pembrolizumab prolongs survival in patients with squamous cell carcinoma

Monoclonal antibody pembrolizumab prolongs survival in patients with squamous cell carcinoma

Inexpensive and effective drug does not reduce major adverse cardiovascular event rates

Inexpensive and effective drug does not reduce major adverse cardiovascular event rates

Atopic dermatitis found to be highly prevalent among adults in the U.S.

Atopic dermatitis found to be highly prevalent among adults in the U.S.